Business Wire

Wisdom Launches New Short-form Audio Format ‘Voice Answers’ in Bid to Solve Social Audio’s Biggest Challenge

22.11.2022 14:17:00 EET | Business Wire | Press release

Share

Wisdom, a social audio app that facilitates one-to-one meaningful conversations, today launches a pioneering new format, ‘Voice Answers’, an asynchronous short-form audio take on the traditional questions and answers format.

Voice Answers was designed to overcome the limitations associated with the live social audio format, popularised by Clubhouse. Now the centerpiece of the app, ‘Voice Answers’ delivers an algorithmically curated feed of wise answers to self-discovery questions like “Describe your idea of a perfect day.” to mentoring questions like “How do I break into the film industry?” to life hack questions like “How do I set boundaries in a relationship?”

Social Audio has demonstrated tremendous promise, with platforms like Clubhouse, Spotify, Twitter, Discord and LinkedIn rolling out social audio experiences to hundreds of millions of users. However, social audio has recently been much maligned, with recent headlines including “Is social audio already dead?” and “The Rise And Fall Of Social Audio.”

Dayo Akinrinade founder and CEO of Wisdom comments: “The biggest challenge with social audio today is its low listening value-to-word ratio. While podcasts are carefully planned and produced, social audio tends to be more freewheeling and, as a result, the content quality is less reliable. Another challenge is the consumption of live audio content being limited to whomever happens to be listening at a given time. Inspired by TikTok’s content-first algorithm and short-video format, my goal with Voice Answers' asynchronous short-form audio format, is to bring elements of TikTok’s innovation to social audio by preserving the excitement of live conversations, whilst also solving the low listening value-to-word ratio problem that's endemic to the live social audio format that Clubhouse pioneered.”

With today’s launch of Voice Answers, the Wisdom app opens to a voice answer, which the user can listen to or swipe. Each swipe informs the machine-learning algorithm, helping improve content recommendations to provide a stream of personalised, high-quality answers.

To be creator-friendly, Voice Answers are restricted to less than 60 seconds and Wisdom auto-generates an audiogram for each Voice Answer, which creators can easily share on other social networks.

Dayo continues: “Questions and answers are powerful tools to unlock insights and gain a deeper understanding of who we are and the world around us. Early in my career, as a black woman in tech, I lacked access to wise people, which hampered my progression. The Voice Answers format is positioned to empower us to share our wisdom with the world, whilst simultaneously pioneering a new short form asynchronous audio format which I hope will overcome the current challenges associated with social audio.”

Download Wisdom for Android on Google Play store here
Download Wisdom for iOS on Apple App Store here

—---- END PRESS RELEASE —--

Notes to the Editor
A selection of supporting hi-res feature images can be found on Google Drive here

About Wisdom
Wisdom is a venture-backed social audio app on a mission to leave the world a bit wiser than we found it. Wisdom connects you for live one-to-one conversations and Q&A, centered on knowledge-sharing and self-discovery. Within a year of launch, Wisdom was awarded Apple’s App Store ‘App of the Day’ twice and TechRadar’s ‘Best Android Apps of 2022’.

Wisdom is a pioneer in the social audio space having created ‘Voice Answers’ an asynchronous, short-form audio take on the traditional Q&A format, which delivers an algorithmically curated feed of high-quality voice answers.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Danielle Zhu or Sarah Herrera from Thinking Hat PR:
danielle@thinkinghatpr.com
sarahh@thinkinghatpr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 17:44:00 EET | Press release

Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the production line. In-Factory Profile Provisioning (IFPP) addresses this challenge by enabling conne

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye